Unknown

Dataset Information

Examining the risk of depression or self-harm associated with incretin-based therapies used to manage hyperglycaemia in patients with type 2 diabetes: a cohort study using the UK Clinical Practice Research Datalink.


ABSTRACT:

Objectives

To compare population-based incidence rates of new-onset depression or self-harm in patients initiating incretin-based therapies with that of sulfonylureas (SU) and other glucose-lowering agents.

Design

Population-based cohort study.

Setting

Patients attending primary care practices registered with the UK-based Clinical Practice Research Datalink (CPRD).

Participants

Using the UK-based CPRD, we identified two incretin-based therapies cohorts: (1) dipeptidyl peptidase-4 inhibitor (DPP-4i)-cohort, consisting of new users of DPP-4i and SU and (2) glucagon-like peptide-1 receptor agonists (GLP-1RA)-cohort, consisting of new users of GLP-1RA and SU, between January 2007 and January 2016. Patients with a prior history of depression, self-harm and other ser

SUBMITTER: Gamble JM 

PROVIDER: S-EPMC6194463 | biostudies-literature | 2018 Oct

REPOSITORIES: biostudies-literature